1
|
Matsuda A, Matsuda T, Shibata A, Katanoda
K, Sobue T and Nishimoto H: Japan Cancer Surveillance Research
Group: Cancer incidence and incidence rates in Japan in 2008: A
study of 25 population-based cancer registries for the monitoring
of cancer incidence in Japan (MCIJ) project. Jpn J Clin Oncol.
44:388–396. 2014. View Article : Google Scholar : PubMed/NCBI
|
2
|
Katanoda K, Hori M, Matsuda T, Shibata A,
Nishino Y, Hattori M, Soda M, Ioka A, Sobue T and Nishimoto H: An
updated report on the trends in cancer incidence and mortality in
Japan. Jpn J Clin Oncol. 45:390–401. 2015. View Article : Google Scholar : PubMed/NCBI
|
3
|
Peto R, Boreham J, Clarke M, Davies C and
Beral V: UK and USA breast cancer deaths down 25% in year 2000 at
ages 20–69 years. Lancet. 355:18222000. View Article : Google Scholar : PubMed/NCBI
|
4
|
Perou CM, Sørlie T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
et al: Molecular portraits of human breast tumours. Nature.
406:747–752. 2000. View
Article : Google Scholar : PubMed/NCBI
|
5
|
Harbeck N, Thomssen C and Gnant M: St.
Gallen 2013: Brief preliminary summary of the consensus discussion.
Breast Care (Basel). 8:102–109. 2013. View Article : Google Scholar : PubMed/NCBI
|
6
|
Goldhirsch A, Wood WC, Coates AS, Gelber
RD, Thürlimann B and Senn HJ: Panel members: Strategies for
subtypes-dealing with the diversity of breast cancer: Highlights of
the St. Gallen international expert consensus on the primary
therapy of early breast cancer 2011. Ann Oncol. 22:1736–1747. 2011.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Falck AK, Bendahl PO, Chebil G, Olsson H,
Fernö M and Rydén L: Biomarker expression and St Gallen molecular
subtype classification in primary tumours, synchronous lymph node
metastases and asynchronous relapses in primary breast cancer
patients with 10 years' follow-up. Breast Cancer Res Treat.
140:93–104. 2013. View Article : Google Scholar : PubMed/NCBI
|
8
|
Marcus AI, Peters U, Thomas SL, Garrett S,
Zelnak A, Kapoor TM and Giannakakou P: Mitotic kinesin inhibitors
induce mitotic arrest and cell death in taxol-resistant and
-sensitive cancer cells. J Biol Chem. 280:11569–11577. 2005.
View Article : Google Scholar : PubMed/NCBI
|
9
|
Miglarese MR and Carlson RO: Development
of new cancer therapeutic agents targeting mitosis. Expert Opin
Investig Drugs. 15:1411–1425. 2006. View Article : Google Scholar : PubMed/NCBI
|
10
|
Huszar D, Theoclitou ME, Skolnik J and
Herbst R: Kinesin motor proteins as targets for cancer therapy.
Cancer Metastasis Rev. 28:197–208. 2009. View Article : Google Scholar : PubMed/NCBI
|
11
|
Kaestner P and Bastians H: Mitotic drug
targets. J Cell Biochem. 111:258–265. 2010. View Article : Google Scholar : PubMed/NCBI
|
12
|
Sharp DJ, Rogers GC and Scholey JM:
Microtubule motors in mitosis. Nature. 407:41–47. 2000. View Article : Google Scholar : PubMed/NCBI
|
13
|
Miki H, Setou M, Kaneshiro K and Hirokawa
N: All kinesin superfamily protein, KIF, genes in mouse and human.
Proc Natl Acad Sci USA. 98:7004–7011. 2001. View Article : Google Scholar : PubMed/NCBI
|
14
|
Kamal A and Goldstein LS: Principles of
cargo attachment to cytoplasmic motor proteins. Curr Opin Cell
Biol. 14:63–68. 2002. View Article : Google Scholar : PubMed/NCBI
|
15
|
Karcher RL, Deacon SW and Gelfand VI:
Motor-cargo interactions: The key to transport specificity. Trends
in Cell Biol. 12:21–27. 2002. View Article : Google Scholar
|
16
|
Vale RD: The molecular motor toolbox for
intracellular transport. Cell. 112:467–480. 2003. View Article : Google Scholar : PubMed/NCBI
|
17
|
Kline-Smith SL and Walczak CE: Mitotic
spindle assembly and chromosome segregation: Refocusing on
microtubule dynamics. Mol Cell. 15:317–327. 2004. View Article : Google Scholar : PubMed/NCBI
|
18
|
Mayr MI, Hümmer S, Bormann J, Grüner T,
Adio S, Woehlke G and Mayer TU: The human kinesin Kif18A is a
motile microtubule depolymerase essential for chromosome
congression. Curr Biol. 17:488–498. 2007. View Article : Google Scholar : PubMed/NCBI
|
19
|
Stumpff J, von Dassow G, Wagenbach M,
Asbury C and Wordeman L: The kinesin-8 motor Kif18A suppresses
kinetochore movements to control mitotic chromosome alignment. Dev
Cell. 14:252–262. 2008. View Article : Google Scholar : PubMed/NCBI
|
20
|
Gardner MK, Odde DJ and Bloom K: Kinesin-8
molecular motors: Putting the brakes on chromosome oscillations.
Trends Cell Biol. 18:307–310. 2008. View Article : Google Scholar : PubMed/NCBI
|
21
|
Zhang C, Zhu C, Chen H, Li L, Guo L, Jiang
W and Lu SH: Kif18A is involved in human breast carcinogenesis.
Carcinogenesis. 31:1676–1684. 2010. View Article : Google Scholar : PubMed/NCBI
|
22
|
Nagahara M, Nishida N, Iwatsuki M,
Ishimaru S, Mimori K, Tanaka F, Nakagawa T, Sato T, Sugihara K,
Hoon DS and Mori M: Kinesin 18A expression: Clinical relevance to
colorectal cancer progression. Int J Cancer. 129:2543–2552. 2011.
View Article : Google Scholar : PubMed/NCBI
|
23
|
Rucksaken R, Khoontawad J, Roytrakul S,
Pinlaor P, Hiraku Y, Wongkham C, Pairojkul C, Boonmars T and
Pinlaor S: Proteomic analysis to identify plasma orosomucoid 2 and
kinesin 18A as potential biomarkers of cholangiocarcinoma. Cancer
Biomark. 12:81–95. 2012.PubMed/NCBI
|
24
|
Liao W, Huang G, Liao Y, Yang J, Chen Q,
Xiao S, Jin J, He S and Wang C: High KIF18A expression correlates
with unfavorable prognosis in primary hepatocellular carcinoma.
Oncotarget. 5:10271–10279. 2014. View Article : Google Scholar : PubMed/NCBI
|
25
|
Mukai H, Aihara T, Yamamoto Y, Takahashi
M, Toyama T, Sagara Y, Yamaguchi H, Akabane H, Tsurutani J, Hara F,
et al: The Japanese Breast Cancer Society Clinical Practice
Guideline for systemic treatment of breast cancer. Breast Cancer.
22:5–15. 2015. View Article : Google Scholar : PubMed/NCBI
|
26
|
Wolff AC, Hammond ME, Schwartz JN, Hagerty
KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer
A, et al: American Society of Clinical Oncology; College of
American Pathologists: American Society of Clinical
Oncology/College of American Pathologists guideline recommendations
for human epidermal growth factor receptor 2 testing in breast
cancer. J Clin Oncol. 25:118–145. 2007. View Article : Google Scholar : PubMed/NCBI
|
27
|
Komoike Y, Inokuchi M, Itoh T, Kitamura K,
Kutomi G, Sakai T, Jinno H, Wada N, Ohsumi S and Mukai H: Japanese
Breast Cancer Society: Japan Breast Cancer Society clinical
practice guideline for surgical treatment of breast cancer. Breast
Cancer. 22:37–48. 2015. View Article : Google Scholar : PubMed/NCBI
|
28
|
Gradishar WJ, Anderson BO, Blair SL,
Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH,
Goldstein LJ, et al: National Comprehensive Cancer Network Breast
Cancer Panel: Breast cancer version 3.2014. J Natl Compr Canc Netw.
12:542–590. 2014.PubMed/NCBI
|
29
|
Atalay C: New concepts in axillary
management of breast cancer. World J Clin Oncol. 5:895–900. 2014.
View Article : Google Scholar : PubMed/NCBI
|
30
|
Giuliano AE, Dale PS, Turner RR, Morton
DL, Evans SW and Krasne DL: Improved axillary staging of breast
cancer with sentinel lymphadenectomy. Ann Surg. 222:394–399;
discussion 399–401. 1995. View Article : Google Scholar : PubMed/NCBI
|
31
|
Ollila DW, Brennan MB and Giuliano AE: The
role of intraoperative lymphatic mapping and sentinel
lymphadenectomy in the management of patients with breast cancer.
Adv Surg. 32:349–364. 1999.PubMed/NCBI
|